Medpace (NASDAQ:MEDP) Updates FY 2025 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share guidance of 11.930-12.690 for the period, compared to the consensus earnings per share estimate of 12.940. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.

Medpace Stock Up 0.1 %

Shares of Medpace stock opened at $354.51 on Tuesday. Medpace has a 12 month low of $302.01 and a 12 month high of $459.77. The stock has a market cap of $11.02 billion, a PE ratio of 31.04, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. The business has a fifty day simple moving average of $343.88 and a 200-day simple moving average of $349.52.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Analysts expect that Medpace will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Redburn Atlantic started coverage on Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 target price on the stock. TD Cowen reduced their price target on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Truist Financial dropped their price objective on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Finally, Robert W. Baird lifted their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.